YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.

Van Yüzüncü Yıl Üniversitesi

Permanent URI for this communityhttps://hdl.handle.net/20.500.14720/1

Browse

Browsing Van Yüzüncü Yıl Üniversitesi by Language "it"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Article
    B-Vak Shows Positive Impact on Arterio-Venous Fistula Patency
    (2012) Odabaşi, D.; Caner, Ş.; Ekima, H.
    Objective: The purpose of this study is to investigate the effect of B-VAK (Mini Wound Drainage System) application to prevent hematoma after arterio-venous fistula (AVF) surgery on AVF patency. Material and Methods: In our clinic between January 2008 and January 2011, 100 patients who were diagnosed as end stage renal failure (ESRF) AVFs created, purposed for hemodialysis (HD) treatment After randomization 50 patients had B-VAX application (Group 1). Groups compared according to hematoma and fistula thrombosis. Results: There were 28 (56%) male, 22 (44%) female in B-VAX applied patients (Group 1). Average age was 34,1 ± 14. Avenge ESRF duration was 86±34 months. Average AVF flow was 470±107 mL. There were hematoma in 4 (8%) and thrombosis in 3 (6%) patients. After averaged 26±4 months fallow-up 7 (14%) patients AVF's became nonfunctional. There were 26 (%52) male, 24 (%48) female in Group 2. Average age was 34,1 ± 14 Average ESRF duration was 83 ± 31months. Average AVF flow was 490±110 mL. There were hematoma in 9 (18%) and thrombosis in 7 (14%) patients. After avaraged 24 ± 4 months fallow-up 11(22%) patients AVF's became nonfunctional. Conclusion: Hematoma is the principal cause of early failure of AVF creation in ESRF patients who needs HD treatment and B-VAX application may serve positive impact in patency of AVF by decreasing the incidence of hematoma. Copyright © 2012 by Turkiye Klinikleri.